Treatment of pulmonary hypertension with the continuous infusion of a prostacyclin analogue, iloprost

Heart

Volumn 79, Issue 2, 1998, Pages 175-179

  Higenbottam, T W ^a,c   Butt, A Y ^b   Dinh Xaun, A T ^a   Takao, M ^a   Cremona, G ^a   Akamine, S ^a  

^a UNIVERSITY OF SHEFFIELD   (United Kingdom)

^b PAPWORTH HOSPITAL   (United Kingdom)

^c UNIVERSITY OF SHEFFIELD   (United Kingdom)

Author keywords

Iloprost; Prostacyclin; Pulmonary hypertension; Vasodilatation

Indexed keywords

ILOPROST; PROSTACYCLIN; VASODILATOR AGENT;

ADULT; ARTICLE; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTINUOUS INFUSION; DRUG EFFECT; EXERCISE; FEMALE; HEART CATHETERIZATION; HUMAN; MALE; OXYGEN SATURATION; PRIORITY JOURNAL; PULMONARY HYPERTENSION; THROMBOEMBOLISM; TREATMENT OUTCOME; VASODILATATION;

EID: 0031920988     PISSN: 13556037     EISSN: None     Source Type: Journal    
DOI: 10.1136/hrt.79.2.175     Document Type: Article

References (20)

1. Fuster V, Steele PM, Edwards WD, et al. Primary pulmonary hypertension: natural history and importance of thrombosis. Circulation 1984;70:580 7.
2. D'Alonzo GE, Barst RJ, Ayres SM, et al. Survival in patients with primary pulmonary hypertension. Ann Intern Med 1991;115:343 9.
3. Rich S, Dantzker DR, Ayres SM, et al. Primary pulmonary hypertension. A national prospective study. Ann Intern Med 1987;107:216-23.
4. Rich S, Brundage BH. High dose calcium channel blocking therapy for primary pulmonary hypertension: evidence for long-term reduction in pulmonary arterial pressure and regression of right ventricular hypertrophy. Circulation 1987;76:135-41.
5. Rich S, Kaufmann E, Levy P. The effect of high doses of calcium channel blockers on survival in primary pulmonary hypertension. N Engl J Med 1992;327:76-81.
6. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-8.
7. Higenbottam TW, Spiegelhalter D, Scott J, et al. Prostacyclin (epoprostenol) and heart lung transplantation as treatments of severe pulmonary hypertension. Br Heart J 1993; 70:366-70.
8. Butt AY, Cremona G, Sharples L, et al. Continuous infusion of prostacyclin (PGL) improves survival in severe pulmonary hypertension [abstract]. J Am Coll Cardiol 1995; (suppl):221A
9. Barst R, Rubin L, Long W, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
10. Higenbottam T. The place of prostacyclin in the clinical management of primary pulmonary hypertension. Am Rev Respir Dis 1987;136:782-5.
11. Barst RJ, Rubin LJ, McGoon MD, et al. Survival in primary pulmonary hypertension with long-term continuous intravenous prostacyclin. Ann Intern Med 1994;121:409 15.
12. Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther 1984;36:464-9.
13. Scott JP, Higenbottam TW, Wallwork J. The acute effect of the synthetic prostacyclin analogue iloprost in primary pulmonary hypertension. Br J Clin Pharmacol 1990;6:231 4.
14. Butt AY, Higenbottam TW. Primary pulmonary hypertension In: Jackson G, ed. Difficult concepts in cardiology. London: Marin Dunitz, 1994:215-43.
15. Hull RD, Raskob GE, Heish J. The diagnosis of a clinically suspected pulmonary embolism. Practical approaches. Chest 1986;89(suppl):417-25.
16. Haslam RJ, McClenaghan MD. Measurement of circulating prostaglandin. Nature 1981;292:364-7.
17. McGavin CR, Gupta SP, McHardy GJR. Twelve minute walking test for assessing disability in chronic bronchitis. BMJ 1976;i:822-3.
18. De Mata LJ, Gomez-Sanchez MA, Aranzana M, et al. Long-term iloprost infusion therapy for severe pulmonary hypertension in patients with connective tissue disease. Arthritis Rheum 1994;37:1528-33.
19. Schror K, Darius H, Matzky R, et al. The anti platelet and cardiovascular actions of a new carbacyclin derivative (ZK36374) - equipotent to PGI. in vitro. Arch Pharmacol 1981;316:252-5.
20. Bugiardini R, Galvani M, Ferrini D, et al. Effects of iloprost, a stable prostacyclin analog, on exercise capacity and platelet aggregation in stable angina pectoris. Am J Cardiol 1986;58:453-9.